Fig. 2From: Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trialsWeibull models of overall survival for studies depicted in Fig. 1. Time axis is months, vertical axis is proportion aliveBack to article page